ABSTRACT
OBJECTIVE: To evaluate efficacy of alpha;beta arteether in patients of P. falciparum malaria presenting with complications was undertaken in a multicentric clinical trial. METHOD: Each patient who consented to undergo clinical trial with parenteral Arteether was treated with a fixed dose schedule of Arteether given intramuscularly in a dose of 150 mg once a day on three consecutive days. Every patient was followed upto 28 days with clinical, haematological and parasitological monitoring every day upto one week and thereafter at 14, 21 and 28 days. The response was assessed in terms of fever clearance time, parasite clearance time, cure rate and parasite reappearance rate. RESULTS: A total of 211 patients of P. falciparum malaria were included in the study from four centres (Bhilai, Guwahati, Jamshedpur and Rourkela). Results of this study showed that fever clearance time ranged between 24-168 hours, parasite clearance time ranged between 24-120 hours and overall mortality ranged between 4-8.5%. Out of 211, only 14 patients expired during the study, of these, 10 patients expired within first two days i.e. before completing the three day schedule of arteether therapy. Tolerability to arteether injection was good in all these patients and no untoward effects were experienced or reported during the study. Overall cure rate observed in these studies was 93%. CONCLUSION: This study shows a rapid parasite and fever clearance in patients of complicated P. falciparum malaria.
Subject(s)
Adolescent , Adult , Animals , Antimalarials/adverse effects , Artemisinins , Female , Humans , Malaria, Falciparum/drug therapy , Male , Middle Aged , Plasmodium falciparum/drug effects , Prospective Studies , Sesquiterpenes/adverse effectsABSTRACT
Two hundred and sixty seven patients of uncomplicated P. falciparum malaria completed study in a multicentric phase III clinical trial of Arteether. Arteether was given intramuscularly in a dose of 150 mg daily for three consecutive days. Each patient was followed upto 28 days of alpha, beta arteether therapy. The cure rate was 97% with fever clearance time between 1-7 days (24-168 hours) and parasite clearance time between 1-3 days (24-72 hours). Parasite reappearance rate was found to be 3% and reported at only three of the centres. Following the treatment no adverse effect was observed on haematological, biochemical and vital clinical parameters.
Subject(s)
Adolescent , Adult , Aged , Antimalarials/therapeutic use , Artemisinins , Female , Humans , Malaria, Falciparum/drug therapy , Male , Middle Aged , Sesquiterpenes/therapeutic useABSTRACT
Mucormycosis is the name for invasive fungal infection caused by mucorales. The disease is uncommon and produces serious and rapidly fatal infection in patients with serious pre-existing illness. The classical presentation of rhinocerebral mucormycosis is involvement of nasal mucosa with invasion of paranasal sinuses and orbit. We report a case of mucormycosis in an otherwise healthy female who had developed acute renal failure following gastroenteritis.
Subject(s)
Adult , Anti-Bacterial Agents/therapeutic use , Central Nervous System Infections/etiology , Fatal Outcome , Female , Gastroenteritis/complications , Humans , Immunocompetence , Acute Kidney Injury/complications , Mucormycosis/diagnosis , Nose/pathologySubject(s)
Adult , Cerebellar Ataxia/etiology , Herpes Zoster Ophthalmicus/complications , Humans , MaleABSTRACT
Salmonella species is the accepted organism causing osteomyelitis in sickle cell disease. Klebsiella pneumoniae is now emerging as a new etiological agent. We report a case of sickle cell osteomyelitis due to Klebsiella pneumoniae.
Subject(s)
Adult , Anemia, Sickle Cell/complications , Humans , Klebsiella Infections/microbiology , Klebsiella pneumoniae/isolation & purification , Macrophages/physiology , Male , Osteomyelitis/etiologyABSTRACT
Radionuclide ventriculography was performed on 10 normal subjects and 39 patients with sickle cell anemia (10 homozygous and 29 heterozygous sicklers) at rest and after exercise. Their left ventricular (LV) function was assessed in both these situations. The results were then compared within the subgroups. The reduction in ejection fraction (EF) response (47.5 +/- 7 at rest and 46.4 +/- 8 at exercise in homozygous patients, and 52.4 +/- 8 at rest and 54.3 +/- 8 at exercise in heterozygous patients) was significant in both the homozygous and the heterozygous groups but more so in the former group. The diastolic filling was also significantly impaired in the homozygous group (PER 2.64 +/- 0.74, PFR 2.13 +/- 0.42 and PFR/HR 0.014 +/- 0.001). The study statistically demonstrates, that LV filling patterns are altered in the sickle cell patients, even in the absence of clinical symptoms relating to LV dysfunction. This fact may prove to be a marker of sickle cell heart disease. Frequent and significant sickling is probably the cause of more pronounced LV functional abnormalities in homozygous sicklers.